News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 3, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
May 25, 2021 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
May 14, 2021 Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 12, 2021 Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
April 28, 2021 Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
April 21, 2021 Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
April 16, 2021 Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 13, 2021 Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
March 17, 2021 Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
March 10, 2021 Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy